

Neonatal Infection Guideline Update- Committee Meeting

Date: 26 January 2021

Location: Virtual committee meeting by Zoom

Minutes: Final

Committee members present:	
Waqar Shah (WS) (Chair)	Present for notes 1 – 5
Sumiah Al-Azeib (SA)	Present for notes 1 – 5
Jim Gray (JG)	Present for notes 1, part of 2, 3-5
Mark Davies (MD)	Present for notes 1 – 5
Nicole Gannon (NG)	Present for notes 1 – 5
Jane Plumb (JP)	Present for notes 1 – 5
Richard Tubman (RT)	Present for notes 1 - 5
Aung Soe (AS)	Present for notes 1 – 5
Philip Banfield (PB)	Present for notes 3 - 5
Stephanie Jenkins (SJ)	Present for notes 1 – 5
Paul Heath (PH)	Present for notes 1 – 2, part of 3, 4 - 5

In attendance:		
Clare Dadswell (CD)	NICE - Technical Analyst	Present for notes 1 – 5

Chris Harris (CH)	NICE - Project Manager	Present for notes 1 – 5
Kathryn Hopkins (KH)	NICE - Technical Adviser	Present for notes 1 – 5
Catrina Charlton (CC)	NICE - Guideline Commissioning Manager	Present for notes 1 - 5
Nicola Cunliffe (NC)	NICE – Project Manager	Present for notes 1 - 5
Jeremy Dietz (JD)	NICE-Technical Analyst Health Economics	Present for notes 1 – 5
Susan Spiers (SS)	Associate Director – Guideline Updates Team	Present for notes 1 – 2, 4 – 5
Adam Storrow	Business Analyst – Resource Impact	Present for notes 1 – 5

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the 11th meeting on Neonatal infections.

The Chair outlined the objectives of the meeting, which included discussion and consideration of stakeholder consultation comments.

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was: prevention and treatment of neonatal infection.

The Chair and a senior member of the Developer’s team noted that the following members would not participate in a part of the meeting:

- **Jane Plumb** is unable to participate in discussions relating to stakeholder comments from GBSS.

The DOI register was reviewed by the Chair and Committee and the Chair asked everyone to verbally declare any interests that have arisen since the last meeting. These are noted below.

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Nicole Gannon	Health Visitor	Direct financial professional and personal (Travel expenses only)	Co-opted committee member (health visitor) for the NICE pelvic floor dysfunction: prevention and non-surgical management guideline update	Declare and participate
Sumiah Al-Azeib		Non-financial professional and personal interests	Attended Neonatal Parental Nutrition outcomes and efficiency: experience of a 3 in 1 solution (Baxter) held on 25th Sep 2020	Declare and participate
Sumiah Al-Azeib		Non-financial professional and personal interests	Attended Management of Sialorrhoea in paediatric neurodisability patients 'the ins and outs' (Proveca) held on 24th of November	Declare and participate
Sumiah Al-Azeib		Non-financial professional and personal interests	Attended Business case planning Part 1 & 2 (Proveca) held on 26th Nov and 3rd Dec 2020	Declare and participate

The DOIs above were considered by the Chair, no conflict of interest was identified for the meeting.

The Chair asked the Committee if it wanted any changes made to the minutes of the last meeting. The Committee agreed the minutes were a true and accurate account of the meeting which took place on the 9th and 10th September 2020.

2. Stakeholder consultation comments

- **General comments**
- **Information and support**
- **Early-onset risk factors**
- **Late-onset risk factors**

The Chair introduced CD, Technical Analyst, who gave a summary presentation on the stakeholder consultation comments. The Chair led a Committee discussion on the comments.

3. Stakeholder consultation comments

- **Investigations**
- **Antibiotics for late-onset infection**
- **Duration of treatment for late-onset**

The Chair introduced CD, Technical Analyst, who continued the presentation on the stakeholder consultation comments. The Chair led a Committee discussion on the comments.

4. Stakeholder consultation comments

- **Antifungals**
- **Intrapartum antibiotics**
- **PPROM**

The Chair introduced CD, Technical Analyst, who continued the presentation on the stakeholder consultation comments. The Chair led a Committee discussion on the comments. The Chair thanked the Committee for their contributions. The Chair thanked CD for her presentations.

5. AOB, summary and next steps

Attendees of the meeting were invited to raise anything further for discussion under any other business.

CH provided the Committee with an overview of the next key deadlines for this topic.

The Chair thanked the Committee for their time and contributions to the meeting and the overall guideline development.

